Ermital capsules 10000ed n20

Adverse Effects

Allergic reactions: immediate type reactions - urticaria, lacrimation, runny nose, bronchospasm.

On the part of the digestive system: irritation of the gastrointestinal mucosa, as well as in the anus; rarely - diarrhea or constipation, nausea, epigastric discomfort; with long-term use in high doses in patients with cystic fibrosis - strictures in the ileo-cecal region and in the ascending colon.

Other: with prolonged use in high doses - hyperuricuria.

Contraindications

Absolute contraindications:

- hypersensitivity to the drug;

- Hypersensitivity to pancreatic enzymes.

Relative contraindications:

- acute pancreatitis;

- exacerbation of chronic pancreatitis;

- pregnancy.

Pregnancy and breastfeeding

Use during pregnancy is contraindicated.

The use of the drug during lactation (breastfeeding) is possible only in the case when the intended benefit of therapy for the mother outweighs the potential risk to the infant.

Special notes

When taken in high doses, unusual symptoms and side effects from the digestive system should be carefully controlled.

With prolonged use with cystic fibrosis may develop constipation, strictures of the ileum and cecum, colitis.

Overdosage

Symptoms: hyperuricosuria, hyperuricemia.

Treatment: drug withdrawal, symptomatic therapy.

Drug Interactions

When taking the drug Ermital may decrease the absorption of folic acid.

Ermital reduces iron absorption.

During the treatment with Ermital, it is possible to reduce the effectiveness of hypoglycemic agents for oral administration - acarbose and miglitol.

The drug is approved for use as a means of OTC.

Storage conditions

The drug should be stored out of reach of children at a temperature not exceeding 25 ° C. Shelf life - 3 years.